Acorah Software Products - Accounts Production 16.3.350 false true 30 September 2023 7 September 2022 false true No description of principal activity 1 October 2023 30 September 2024 30 September 2024 14341407 S I Qanadilo iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 14341407 2023-09-30 14341407 2024-09-30 14341407 2023-10-01 2024-09-30 14341407 frs-core:CurrentFinancialInstruments 2024-09-30 14341407 frs-bus:PrivateLimitedCompanyLtd 2023-10-01 2024-09-30 14341407 frs-bus:FilletedAccounts 2023-10-01 2024-09-30 14341407 frs-bus:Micro-entities 2023-10-01 2024-09-30 14341407 frs-bus:AuditExempt-NoAccountantsReport 2023-10-01 2024-09-30 14341407 frs-bus:Director1 2023-10-01 2024-09-30 14341407 2022-09-06 14341407 2023-09-30 14341407 2022-09-07 2023-09-30 14341407 frs-core:CurrentFinancialInstruments 2023-09-30
Registered number: 14341407
PHARMACEUTICAL TECHNOLOGY CENTRE LTD
Unaudited Financial Statements
For The Year Ended 30 September 2024
Michael Price Associates Limited
Balance Sheet
Registered number: 14341407
30 September 2024 30 September 2023
£ £
Fixed assets 1,088 1,559
Current assets 160,360 161,813
Creditors: Amounts Falling Due Within One Year (43,175 ) (33,632 )
NET CURRENT ASSETS 117,185 128,181
TOTAL ASSETS LESS CURRENT LIABILITIES 118,273 129,740
Accruals and deferred income (244 ) (1,850 )
NET ASSETS 118,029 127,890
CAPITAL AND RESERVES 118,029 127,890

Notes

1. General Information
PHARMACEUTICAL TECHNOLOGY CENTRE LTD is a private company, limited by shares, incorporated in England & Wales, registered number 14341407 . The registered office is Daresbury Laboratory Sci-Tech Daresbury, Daresbury, Warrington, WA4 4AD.
2. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2023: 1)
1 1
3. Post Balance Sheet Events
Reduction in Share Capital
The directors have resolved to reduce the company's share capital in the next financial year ending 30 Septmeber 2025. This decision was made after the reporting date of these financial statements and is subject to the necessary legal and procedural requirements. The reduction in share capital does not affect the company’s ability to continue as a going concern.
4. Going Concern
The directors will continue to adopt the going concern basis in preparing the financial statements which assumes that the company will continue in operation for the foreseeable future.
Page 0
Page 1
For the year ending 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
S I Qanadilo
Director
25/06/2025